Tracer Biotechnologies, Inc

Tracer Biotechnologies has raised a $10 million Series A round to advance its technology that’s designed to monitor circulating tumor DNA in cancer patients over lengthy periods. The company uses biomarker data to develop its tests that are based on digital polymerase chain reaction, a lab technique to amplify samples so they’re large enough to study in detail. Its tests are designed to track a patient’s molecular response over unlimited time points, helping assess treatments, disease progression and inform clinical trial design. Tracer is pitching its offerings as an alternative to radiographic scans which can be costly and imprecise. “We have really adopted the mantra of simpler, lower cost, more scalable solutions,” Mark Kaganovich, CEO of Tracer Biotechnologies, told Endpoints News . In Tracer’s first major partnership, AstraZeneca will use the technology in some of its clinical trials. Deal terms weren’t disclosed. The funding round was led by the venture capital firm GKCC, with participation from other firms.

NEW YORK--( BUSINESS WIRE )--Tracer Biotechnologies, a next-generation diagnostics company, today announced a multi-year project with AstraZeneca (LSE/STO/Nasdaq: AZN). The agreement will enable AstraZeneca to use Tracer’s circulating tumor DNA (ctDNA) monitoring technology for clinical trials. Tracer has developed a proprietary platform for tumor-informed ctDNA detection based on digital polymerase chain reaction (PCR). Tracer’s platform optimizes ctDNA detection, enabling cost-effective, precise, and scalable testing for patients as an alternative to radiographic imaging. “We are entering a new era of oncology where patients will no longer have to wait for costly and imprecise radiographic scans to assess treatment and disease progression,” said Mark Kaganovich, CEO of Tracer Biotechnologies. “We are proud to work with AstraZeneca to leverage frequent, precise, and cost-effective ctDNA measurement for minimal residual disease detection and treatment response monitoring.” About Tracer Biotechnologies Tracer Biotechnologies is a next-generation diagnostics company. Tracer is the only ultrasensitive ctDNA assay for Molecular Response surveillance. Combining tumor-informed personalization with dPCR allows Tracer to offer cost-effective assays for an unlimited number of timepoints on a study. The Tracer assay is available for blood and urine. For more information, please visit https://tracerbio.com/ .